Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 341 participants.
Also called NCT06297603
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 341 participants
- Sponsor
- Registry
-
NCT06297603
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Israel, Mexico, Puerto Rico, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06297603. Randomized; double masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2026-10-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Retatrutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06297603- Content hash
171f12618f5d39df9e11346e1aaa00bb5a765df5d64070fa9e5536b4d36fad80